<DOC>
	<DOCNO>NCT00516464</DOCNO>
	<brief_summary>Evaluation ranibizumab ease procedure complication proliferative diabetic retinopathy ( PDR ) require vitrectomy .</brief_summary>
	<brief_title>Evaluation Ranibizumab Proliferative Diabetic Retinopathy ( PDR ) Requiring Vitrectomy</brief_title>
	<detailed_description>This open-label , Phase I/II study multiple dose intravitreally administer ranibizumab patient severe NPDR PDR prior , , vitrectomy therapy . 40 subject enrol randomized 3:1 ranibizumab vitrectomy alone . 30 consent , enrolled subject receive 3 intravitreal injection 0.5 mg ranibizumab administer 1-3 week pre-procedure , intraoperatively , 1 month post-vitrectomy .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 20 year Best correct visual acuity 20/40 20/800 study eye Very servere nonproliferative diabetic retinopathy ( ETDRS level 53E ) OR moderate proliferative diabetic retinopathy ( ETDRS level 65 ) Visual reduction attributable diabetic vitreous hemorrhage diabetic macular edema Candidate vitrectomy procedure Pregnancy ( positive Pregnancy test ) lactation Premenopausal woman use adequate contraception . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . Participation another simultaneous medical investigation trial . Visual impairment attributable cause diabetic macular edema diabetic vitreous hemorrhage . Use intraocular periocular corticosteroid within 6 month . History panretinal photocoagulation History macular laser photocoagulation History par plana vitrectomy Prior concomitant treatment ranibizumab , bevacizumab , pegaptanib sodium , either part investigational study offlabel medication . Current treatment systemic infection</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Proliferative Diabetic Retinopathy</keyword>
	<keyword>Vitrectomy</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>